Trenkwalder, Claudia

[["dc.bibliographiccitation.firstpage","946"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Nature Genetics"],["dc.bibliographiccitation.lastpage","948"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Schormair, Barbara"],["dc.contributor.author","Kemlink, David"],["dc.contributor.author","Roeske, Darina"],["dc.contributor.author","Eckstein, Gertrud"],["dc.contributor.author","Xiong, Lan"],["dc.contributor.author","Lichtner, Peter"],["dc.contributor.author","Ripke, Stephan"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Zimprich, Alexander"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Oertel, Wolfgang"],["dc.contributor.author","Bachmann, Cornelius G."],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Frauscher, Birgit"],["dc.contributor.author","Gschliesser, Viola"],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Peglau, Ines"],["dc.contributor.author","Vodicka, Pavel"],["dc.contributor.author","Vavrova, Jana"],["dc.contributor.author","Sonka, Karel"],["dc.contributor.author","Nevsimalova, Sona"],["dc.contributor.author","Montplaisir, Jacques"],["dc.contributor.author","Turecki, Gustavo"],["dc.contributor.author","Rouleau, Guy A."],["dc.contributor.author","Gieger, Christian"],["dc.contributor.author","Illig, Thomas"],["dc.contributor.author","Wichmann, H-Erich"],["dc.contributor.author","Holsboer, Florian"],["dc.contributor.author","Mueller-Myhsok, Bertram"],["dc.contributor.author","Meitinger, Thomas"],["dc.contributor.author","Winkelmann, Juliane"],["dc.date.accessioned","2018-11-07T11:12:40Z"],["dc.date.available","2018-11-07T11:12:40Z"],["dc.date.issued","2008"],["dc.description.abstract","We identified association of restless legs syndrome (RLS) with PTPRD at 9p23-24 in 2,458 affected individuals and 4,749 controls from Germany, Austria, Czechia and Canada. Two independent SNPs in the 5' UTR of splice variants expressed predominantly in the central nervous system showed highly significant P values (rs4626664, P(nominal/lambda corrected) = 5.91 x 10(-10), odds ratio (OR) = 1.44; rs1975197, P(nominal/lambda corrected) = 5.81 x 10(-9), OR 1.31). This work identifies PTPRD as the fourth genome-wide significant locus for RLS."],["dc.identifier.doi","10.1038/ng.190"],["dc.identifier.isi","000258026900008"],["dc.identifier.pmid","18660810"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53717"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1061-4036"],["dc.title","PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","373"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","NEUROREHABILITATION AND NEURAL REPAIR"],["dc.bibliographiccitation.lastpage","381"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Rothkegel, Holger"],["dc.contributor.author","Sommer, Martin"],["dc.contributor.author","Rammsayer, Thomas H."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Paulus, Walter J."],["dc.date.accessioned","2018-11-07T08:30:31Z"],["dc.date.available","2018-11-07T08:30:31Z"],["dc.date.issued","2009"],["dc.description.abstract","Background. Focal single-session repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex has been claimed to be capable of improving motor function in Parkinson's disease. Objective. The authors sought to determine which type of rTMS protocol holds the highest potential for future therapeutic application. Methods. Twenty-two patients with Parkinson's disease received 5 different rTMS protocols on 5 consecutive days in a pseudorandomized and counterbalanced order either in the defined OFF condition or with their usual medication. The protocols tested in the present study included 2 conventional rTMS protocols (0.5 and 10 Hz) as well as the recently introduced theta burst stimulation (cTBS, iTBS) and a sham condition. Cortical excitability, motor performance (pointing movement, pronation-supination, Purdue Pegboard Test, walking), and mood were assessed before and after each session. Results. The authors observed motor training from days 1 to 4, particularly in the group on dopaminergic medication. None of the rTMS paradigms excelled placebo stimulation. The only exception was the Purdue Pegboard Test, in which all active stimulation paradigms yielded slightly stronger effects than sham stimulation. Conclusions. Within a single session, no clinically relevant difference in the rTMS protocols could be detected. Training effects outweigh and may have masked rTMS effects, particularly in the group on dopaminergic mediation."],["dc.identifier.doi","10.1177/1545968308322842"],["dc.identifier.isi","000264876100009"],["dc.identifier.pmid","18978029"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13103"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16906"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Inc"],["dc.relation.issn","1545-9683"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Training Effects Outweigh Effects of Single-Session Conventional rTMS and Theta Burst Stimulation in PD Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1905"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Human Brain Mapping"],["dc.bibliographiccitation.lastpage","1915"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Focke, Niels K."],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Scheewe, Sebstian"],["dc.contributor.author","Pantel, Pia M."],["dc.contributor.author","Bachmann, Cornelius G."],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Ebentheuer, Jens"],["dc.contributor.author","Mohr, Alexander"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2018-11-07T08:50:18Z"],["dc.date.available","2018-11-07T08:50:18Z"],["dc.date.issued","2011"],["dc.description.abstract","Voxel-based morphometry (VBM) shows a differentiated pattern in patients with atypical Parkinson syndrome but so far has had little impact in individual cases. It is desirable to translate VBM findings into clinical practice and individual classification. To this end, we examined whether a support vector machine (SVM) can provide useful accuracies for the differential diagnosis. We acquired a volumetric 3D T1-weighted MRI of 21 patients with idiopathic Parkinson syndrome (IPS), 11 multiple systems atrophy (MSA-P) and 10 progressive supranuclear palsy (PSP), and 22 healthy controls. Images were segmented, normalized, and compared at group level with SPM8 in a classical VBM design. Next, a SVM analysis was performed on an individual basis with leave-one-out cross-validation. VBM showed a strong white matter loss in the mesencephalon of patients with PSP, a putaminal grey matter loss in MSA, and a cerebellar grey matter loss in patients with PSP compared with IPS. The SVM allowed for an individual classification in PSP versus IPS with up to 96.8% accuracy with 90% sensitivity and 100% specificity. In MSA versus IPS, an accuracy of 71.9% was achieved; sensitivity, however, was low with 36.4%. Patients with IPS could not be differentiated from controls. In summary, a voxel-based SVM analysis allows for a reliable classification of individual cases in PSP that can be directly clinically useful. For patients with MSA and IPS, further developments like quantitative MRI are needed. Hum Brain Mapp 32:1905-1915, 2011. (C) 2011 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/hbm.21161"],["dc.identifier.isi","000296850700012"],["dc.identifier.pmid","21246668"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21663"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1065-9471"],["dc.title","Individual Voxel-Based Subtype Prediction can Differentiate Progressive Supranuclear Palsy from Idiopathic Parkinson Syndrome and Healthy Controls"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","878"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","The Lancet Neurology"],["dc.bibliographiccitation.lastpage","886"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2018-11-07T09:11:48Z"],["dc.date.available","2018-11-07T09:11:48Z"],["dc.date.issued","2006"],["dc.description.abstract","Therapy-related augmentation of the symptoms of restless legs syndrome (RLS) is an important clinical problem reported in up to 60% of patients treated with levodopa and, to a lesser extent, with dopamine agonists. The efficacy of low-dose dopaminergic drugs for RLS has been established, but the mode of action is unknown. Here, we review the existing data and conclude that augmentation is a syndrome characterised by a severely increased dopamine concentration in the CNS; overstimulation. of the dopamine D1 receptors compared with D2 receptors in the spinal cord may lead to D1-related pain and generate periodic limb movements; iron deficiency may be a main predisposing factor of augmentation, probably caused by a reduced function of the dopamine transporter; therapy with levodopa or dopamine agonists should remain at low doses and; iron supplementation and opiates are the therapy of choice to counter augmentation."],["dc.identifier.doi","10.1016/S1474-4422(06)70576-2"],["dc.identifier.isi","000240777800023"],["dc.identifier.pmid","16987735"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26801"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lancet Ltd"],["dc.relation.issn","1474-4422"],["dc.title","Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S495"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","S504"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Allen, Richard P."],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","Klein, Christine"],["dc.contributor.author","Nass, Alexander"],["dc.contributor.author","Montagna, Pasquale"],["dc.contributor.author","Oertel, Wolfgang Hermann"],["dc.contributor.author","O'Keeffe, Shaun"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Provini, Federica"],["dc.contributor.author","Pramstaller, Peter P."],["dc.contributor.author","Sieminski, Mariusz"],["dc.contributor.author","Sonka, Karel"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","de Weerd, A. L."],["dc.contributor.author","Wetter, Thomas C."],["dc.contributor.author","Winkelmann, Juliane"],["dc.contributor.author","Zucconi, Marco"],["dc.date.accessioned","2018-11-07T11:07:07Z"],["dc.date.available","2018-11-07T11:07:07Z"],["dc.date.issued","2007"],["dc.description.abstract","The European Restless Leas Syndrome (RLS) Study Group (EURLSSG) is an association of European RLS experts who are actively involved in RLS research. A major aim of the Study Group is the development and continuous improvement of standards for diagnosis and treatment of RLS. Several members developed study designs and evaluation methods in investigator-initiated trials early in the 1990s, and all members have since contributed to many pivotal and nonpivotal drug trials for the treatment of RLS. The recommendations on clinical investigations of pharmacological treatment of RLS patients summarize the group's expertise and knowledge acquired through clinical trials. The recommendations primarily address how to plan and conduct confirmatory, randomized clinical studies in patients with idiopathic RLS. Advice is presented for the diagnosis of RLS and clinical and polysomnographic inclusion and exclusion criteria. Primary and secondary endpoints for an evaluation of efficacy are based on a critical description of validated methods for both short- and long-term trials, also in special populations (children, pregnant women, elderly patients). The recommendations include the assessment of augmentation. Finally, general issues including the evaluation of safety and tolerability, as well as specific neurological and cardiovascular risks and sleep attacks/daytime somnolence, are discussed. The aim of these recommendations is to support research groups or pharmaceutical companies in the design of optimized study protocols. (C) 2007 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.21538"],["dc.identifier.isi","000251605200015"],["dc.identifier.pmid","17530666"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52479"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Scientific Symposium and Augmentation Workshop on Restless Leg Syndrome"],["dc.relation.eventlocation","Max Planck Inst Phys Complex Syst, Munich, GERMANY"],["dc.relation.issn","1531-8257"],["dc.relation.issn","0885-3185"],["dc.title","Clinical trials in restless legs syndrome - Recommendations of the European RLS study group (EURLSSG)"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1511"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","1515"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Tings, T."],["dc.contributor.author","Helmschmied, Kathrin"],["dc.contributor.author","Neubert, K."],["dc.contributor.author","Wuttke, Wolfgang"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2018-11-07T10:43:34Z"],["dc.date.available","2018-11-07T10:43:34Z"],["dc.date.issued","2004"],["dc.description.abstract","Challenge with low-dose apomorphine causes a significant rise in growth hormone (GH) in patients with Parkinson's disease (PD) compared to controls and patients with multiple system atrophy (MSA) who have not previously received dopaminergic treatment. To date, it has not been demonstrated whether an apomorphine-induced rise in GH can still be detected in PD patients who are currently treated with levodopa. We investigated whether an ongoing treatment with levodopa influences the GH response to subcutaneously applied low-dose apomorphine in PD patients. We studied 44 patients with idiopathic PD using the low-dose apomorphine test. Twenty-three patients were under treatment with levodopa and 21 patients were without any dopaminergic therapy. GH and cortisol levels were analyzed at time of injection and 45 minutes and 60 minutes after subcutaneous apomorphine injection. Forty-five minutes after apomorphine injection, there was no significant difference between the mean rise in plasma GH in untreated PD patients compared with levodopa-treated patients (P = 0.235). There was no increase of cortisol levels in each treatment group. Age, sex, duration, and severity of the disease did not show a covariate effect with GH levels. A small group of PD patients (n = 8) treated with dopamine agonists and a small group of patients with MSA (n = 5) as well as patients with vascular parkinsonism (n = 5) did not show any increase of GH. Our data suggest that the apomorphine-induced rise in GH does not depend on previous levodopa treatment in PD patients but, as expected, is blocked by dopamine agonists and is not present in patients with other than idiopathic parkinsonian syndrome. Thus, the low-dose apomorphine test may also be a useful biological marker in the early differential diagnosis of PD patients who have already received levodopa treatment. (C) 2004 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.20244"],["dc.identifier.isi","000225774100023"],["dc.identifier.pmid","15390061"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47084"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0885-3185"],["dc.title","Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1072"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","1075"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Tings, T."],["dc.contributor.author","Schettler, Volker"],["dc.contributor.author","Canelo, M."],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2018-11-07T10:46:05Z"],["dc.date.available","2018-11-07T10:46:05Z"],["dc.date.issued","2004"],["dc.description.abstract","We examined 25 hyperlipidaemic patients with coronary heart disease undergoing regular low-density lipoprotein apheresis (LA) treatment in weekly intervals. In this patient population, half were found to have concomitant restless legs syndrome (RLS). Laboratory investigations suggest that iron metabolism is modified by regular LA treatment and this change may be involved in the pathogenesis of this previously unrecognised form of secondary RLS. Substitution of iron therefore may be a promising line of treatment for LA-induced RLS. (C) 2004 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.20102"],["dc.identifier.isi","000223830200012"],["dc.identifier.pmid","15372599"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47665"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0885-3185"],["dc.title","Impact of regular LDL apheresis on the development of restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.volume","80"],["dc.contributor.author","Heide, Anne-Catherine"],["dc.contributor.author","Winkler, Tobias"],["dc.contributor.author","Nitsche, Michael"],["dc.contributor.author","Heide, Wolfgang"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Bachmann, Cornelius"],["dc.date.accessioned","2018-11-07T09:28:11Z"],["dc.date.available","2018-11-07T09:28:11Z"],["dc.date.issued","2013"],["dc.identifier.isi","000332068601124"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30716"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","65th Annual Meeting of the American-Academy-of-Neurology (AAN)"],["dc.relation.eventlocation","San Diego, CA"],["dc.relation.issn","1526-632X"],["dc.relation.issn","0028-3878"],["dc.title","Is Transcutaneous Spinal Direct Current Stimulation Efficient in Symptomatic Treatment of Patients with Idiopathic Restless Legs Syndrome?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e2622"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Dressel, Ralf"],["dc.contributor.author","Schindehuette, Jan"],["dc.contributor.author","Kuhlmann, Tanja"],["dc.contributor.author","Elsner, Leslie"],["dc.contributor.author","Novota, Peter"],["dc.contributor.author","Baier, Paul Christian"],["dc.contributor.author","Schillert, Arne"],["dc.contributor.author","Bickeboeller, Heike"],["dc.contributor.author","Herrmann, Thomas R."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Mansouri, Ahmed"],["dc.date.accessioned","2018-11-07T11:13:02Z"],["dc.date.available","2018-11-07T11:13:02Z"],["dc.date.issued","2008"],["dc.description.abstract","Embryonic stem (ES) cells have the potential to differentiate into all cell types and are considered as a valuable source of cells for transplantation therapies. A critical issue, however, is the risk of teratoma formation after transplantation. The effect of the immune response on the tumorigenicity of transplanted cells is poorly understood. We have systematically compared the tumorigenicity of mouse ES cells and in vitro differentiated neuronal cells in various recipients. Subcutaneous injection of 1 x 10(6) ES or differentiated cells into syngeneic or allogeneic immunodeficient mice resulted in teratomas in about 95% of the recipients. Both cell types did not give rise to tumors in immunocompetent allogeneic mice or xenogeneic rats. However, in 61% of cyclosporine A-treated rats teratomas developed after injection of differentiated cells. Undifferentiated ES cells did not give rise to tumors in these rats. ES cells turned out to be highly susceptible to killing by rat natural killer (NK) cells due to the expression of ligands of the activating NK receptor NKG2D on ES cells. These ligands were downregulated on differentiated cells. The activity of NK cells which is not suppressed by cyclosporine A might contribute to the prevention of teratomas after injection of ES cells but not after inoculation of differentiated cells. These findings clearly point to the importance of the immune response in this process. Interestingly, the differentiated cells must contain a tumorigenic cell population that is not present among ES cells and which might be resistant to NK cell-mediated killing."],["dc.identifier.doi","10.1371/journal.pone.0002622"],["dc.identifier.isi","000264065800024"],["dc.identifier.pmid","18612432"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8264"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53801"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 2.5"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.5"],["dc.title","The Tumorigenicity of Mouse Embryonic Stem Cells and In Vitro Differentiated Neuronal Cells Is Controlled by the Recipients' Immune Response"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","255"],["dc.bibliographiccitation.lastpage","265"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Paulus, Walter"],["dc.date.accessioned","2021-06-02T10:44:31Z"],["dc.date.available","2021-06-02T10:44:31Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/bs.apha.2019.02.002"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87072"],["dc.notes.intern","DOI-Import GROB-425"],["dc.publisher","Elsevier"],["dc.relation.isbn","978-0-12-816758-8"],["dc.relation.ispartof","Pharmacology of Restless Legs Syndrome (RLS)"],["dc.title","Pharmacological treatments of augmentation in restless legs syndrome patients"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]